Protocol Ledger

NCT06315231 · Phase II · RECRUITING

Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients

Interventional Phase II clinical trial protocol NCT06315231 sponsored by Simcere Pharmaceutical Co in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-04-08 Enrollment: 226 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06315231
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)226 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06315231
Protocol FieldVerified Registry Value
NCT IdentifierNCT06315231
Consolidated Lead SponsorSimcere Pharmaceutical Co
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment226 participants (ESTIMATED)
Registered Start Date2024-04-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI